Peixe Rosa — Life Sciences & Translational Medicine
AMPARO
Programmable Innate Immunity
Biotechnology | Infectious Disease | Biological Preparedness
A New Approach to Infectious Disease
AMPARO is a biotechnology platform focused on developing immunobiological interventions that recognize pathogens at the earliest stages of infection.
Its approach builds upon the natural pathogen-recognition capabilities of mannose-binding lectin (MBL), a component of the human innate immune system.
Through recombinant protein engineering, the platform investigates how pathogen recognition and immune-response modulation can be combined to support the development of new therapeutic and preventive interventions.
AMPARO is designed as a multi-program platform, capable of advancing different applications from a common scientific and technological foundation.
AMPARO — US$18 Million Co-Investment Opportunity
The Commercial Opportunity
Infectious diseases, emerging pathogens, antimicrobial resistance and pandemic preparedness create substantial demand for new biological technologies.
AMPARO's commercial proposition is the development of a portfolio of therapeutic candidates and associated platform technologies rather than dependence on a single product.
Potential applications include tuberculosis, respiratory viral infections, fungal infections, vulnerable patient populations and biological preparedness.
Its intended commercial pathways include pharmaceutical licensing, strategic development partnerships, technology agreements and appropriately authorized product commercialization.
The platform also presents potential applications for public-health institutions and government biological-preparedness programs.
Each application is subject to its own development, validation and regulatory requirements.
Scientific Foundation & Validation
AMPARO builds upon a scientific research foundation originating in 1998, including longstanding Brazilian research into mannose-binding lectin and its potential therapeutic applications.
The underlying research has involved scientific expertise and institutional relationships associated with Pernambuco's biomedical and translational research ecosystem.
The platform's technical development includes engineered recombinant MBL approaches intended to preserve pathogen recognition while modulating complement activation and inflammatory responses.
The underlying scientific foundation and accumulated technical development have been assessed by Of Joseph PB&T as sufficiently advanced to support selection for external co-investment.
The next stage emphasizes independent platform validation, advancement of lead therapeutic programs, regulatory preparation and manufacturing readiness.
Specific clinical effectiveness, safety, regulatory authorization and commercial performance remain subject to further evidence and applicable approvals.
A Multi-Program Biotechnology Platform
AMPARO's architecture combines four technological capabilities:
Pathogen Recognition
Engineered molecules designed to identify biological signatures associated with target pathogens.
Delivery Systems
Development of appropriate respiratory or systemic delivery approaches according to the therapeutic application.
Pathogen Mapping
Scientific characterization of potential targets and relevant biological interactions.
Rapid Response Development
A repeatable development framework intended to support additional therapeutic programs as scientific evidence and technical capabilities advance.
This platform approach creates the possibility of developing several commercial assets from related scientific foundations.
Programs under consideration include tuberculosis, respiratory viruses, fungal infections and biological preparedness.
The development status of each program must be distinguished from the overall scientific foundation of the platform.
Purpose-Built Independent Enterprise
New company. Established scientific foundations.
AMPARO's co-investment structure is designed to support the establishment and capitalization of an independent biotechnology company.
Of Joseph PB&T will arrange the contribution, transfer or licensing of the applicable scientific, technical and commercial assets necessary for the company's independent business objectives, subject to verified ownership and definitive agreements.
The enterprise will be established with clearly defined governance, obligations, operating capabilities and a commercial development mandate.
Management will be strategically selected from a global pool of qualified biotechnology, pharmaceutical, regulatory, scientific and commercial professionals.
This structure is intended to provide a transparent operating foundation without unrelated historical corporate obligations, supported by appropriate asset and liability due diligence.
The Peixe Rosa Advantage
AMPARO's development within the Peixe Rosa ecosystem provides a distinctive institutional and operational foundation.
Through applicable institutional arrangements, Peixe Rosa provides access to scientific, technical, laboratory and clinical environments relevant to the continued development of immunobiological technologies.
Of Joseph PB&T's established Brazilian operations contribute scientific and operational development capabilities, institutional relationships and meaningful cost advantages.
The enterprise's development strategy combines these Brazilian capabilities with internationally oriented scientific standards, regulatory preparation, manufacturing requirements and commercial pathways.
This approach is intended to support efficient development while establishing the evidence and operating capabilities required for participation in global biotechnology markets.
Capital Requirements
US$18 MILLION
Initial Co-Investment Capitalization
The proposed capitalization is intended to establish and advance AMPARO as an independent biotechnology enterprise.
- Corporate establishment, governance and operating capabilities.
- Asset contribution, intellectual-property and commercial-rights structuring.
- Platform validation and advancement of lead therapeutic programs.
- Preclinical development and preparation for investigational regulatory submissions.
- Regulatory and manufacturing readiness.
- Development of licensing-ready technical and commercial packages.
- Biological-preparedness applications.
- Scientific data infrastructure and relevant AI capabilities.
- Operating requirements and appropriate reserves.
Additional capital may be introduced as the enterprise progresses into subsequent clinical development, manufacturing and commercialization.
Detailed participation terms are provided privately to qualified investors.
Development Milestones
The proposed initial development program is organized around a 12–18 month milestone horizon, subject to technical execution, regulatory requirements and available resources.
Principal objectives include:
Platform Validation
Advance independent validation of the core engineered-MBL technology and its proposed applications.
Lead Therapeutic Programs
Progress selected programs toward investigational regulatory readiness.
Commercial Licensing Preparation
Develop technical, intellectual-property, regulatory and commercial documentation for prospective pharmaceutical partners.
Manufacturing & Regulatory Readiness
Establish the requirements for scalable production, quality systems and applicable regulatory submissions.
Enterprise Development
Establish the independent company's management, governance, strategic partnerships and commercial operating capabilities.
These are proposed objectives, not completed milestones or guaranteed outcomes.
Enterprise Value Creation
AMPARO's investment proposition recognizes the value created through its longstanding scientific foundation, accumulated research, technical development, know-how, intellectual assets and prior sponsor investment.
Of Joseph PB&T's stewardship and early development work precede external co-investment.
The next phase is intended to create additional enterprise value through independent platform validation, advancement of therapeutic programs, intellectual-property protection, regulatory progress, strategic partnerships and potential licensing transactions.
A multi-program platform may create several commercial opportunities with distinct development schedules and licensing pathways.
Detailed participation terms are provided privately to qualified investors.
Commercialization & Monetization
AMPARO's intended commercialization model includes:
Therapeutic Program Licensing
Licensing selected programs to pharmaceutical and biotechnology partners as supporting evidence and commercial readiness develop.
Platform Technology Partnerships
Collaborations involving relevant platform capabilities and additional therapeutic applications.
Strategic Institutional Programs
Commercial and development relationships with qualified healthcare, public-health and biological-preparedness organizations.
Product Commercialization
Potential direct or partnered commercialization of authorized products, subject to clinical development and regulatory approval.
The April 2026 investment materials contemplate potential early licensing activity within approximately 12–24 months. This is a proposed planning horizon, dependent on program readiness and commercial agreements.
Potential longer-term outcomes include strategic transactions, acquisition opportunities, further enterprise capitalization and investor liquidity.